darolutamide

Contraindicated in:

End-stage renal disease;
Severe hepatic impairment.

Use Cautiously in:

Severe renal impairment (↓ dose);
Moderate hepatic impairment (↓ dose);
Rep: Men with female partners of reproductive potential;
Pedi: Safety and effectiveness not established in children.

Adv. Reactions/Side Effects ⬆ ⬇

CV: ISCHEMIC HEART DISEASE, HF

Derm: rash

GI: hyperbilirubinemia, ↑liver enzymes

Hemat: neutropenia

Neuro: fatigue, SEIZURES

Interactions ⬆ ⬇

Drug-drug:

Concurrent use with a combined P-glycoprotein and strong or moderate CYP3A4 inducer, including rifampin, may ↓ levels and effectiveness; avoid concurrent use.
Concurrent use with a combined P-glycoprotein and strong CYP3A4 inhibitor, including itraconazole, may ↑ levels and the risk of toxicity; avoid concurrent use.
May ↑ levels of BCRP substrates, including rosuvastatin; avoid concurrent use.

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

Patients should also be taking a gonadotropin-releasing hormone (GnRH) analog or should have undergone a bilateral orchiectomy.
PO (Adults ): 600 mg twice daily until disease progression or unacceptable toxicity.

Renal Impairment

PO (Adults ): CCr 15–29 mL/min: 300 mg twice daily.

Hepatic Impairment

PO (Adults ): Moderate hepatic impairment: 300 mg twice daily.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Acts as an androgen receptor inhibitor, preventing the binding of androgen; decreases proliferation and induces cell death of prostate cancer cells.

Therapeutic effects:

Decreased growth and spread of prostate cancer.

Classifications ⬆ ⬇

Therapeutic Classification: antineoplastics

Pharmacologic Classification: androgen receptor inhibitors

Pharmacokinetics ⬆ ⬇

Absorption: 30% absorbed following oral administration; absorption ↑ with food.

Distribution: Extensively distributed to tissues.

Protein Binding: Darolutamide: 92%; Keto-darolutamide: 99.8%.

Metabolism/Excretion: Primarily metabolized in the liver by the CYP3A4 isoenzyme as well as by UGT1A1 and UGT1A9 to an active metabolite (keto-darolutamide). Primarily excreted in urine (63%, 7% as unchanged drug) and 32% excreted in feces (30% as unchanged drug).

Half-Life: 20 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	4 hr	unknown

Patient/Family Teaching ⬆ ⬇

Instruct patient to take darolutamide as directed. Take missed doses as soon as remembered, but do not take two doses together to make up for a missed dose. Advise patient to read Patient Information before starting therapy and with each Rx refill in case of changes.
Inform patient of importance of continuing therapy with gonadotropin-releasing hormone during therapy with darolutamide.
Advise patient darolutamide may increase risk for seizures. Avoid activities where a sudden loss of consciousness could cause serious harm to yourself or others. Tell your health care professional right away if you have loss of consciousness or seizure.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Rep: May cause fetal harm. Advise male patients with female partners of reproductive potential to use effective contraception and avoid breastfeeding during and for 1 wk after last dose. Inform patient that darolutamide may impair fertility.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

50419- Bayer HealthCare Pharmaceuticals Inc.
- 50419-395- NUBEQA
  - 50419-395-01- 1 BOTTLE in 1 CARTON (50419-395-01) > 120 TABLET, FILM COATED in 1 BOTTLE

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇